Division of Gastroenterology & Hepatology Research
Our research goals at NYU Langone’s Division of Gastroenterology and Hepatology are to provide access to the latest treatments in the pipeline to our patients and to advance knowledge of gastroenterology and hepatology through innovative basic science, translational research, and clinical trials. We aim to foster a spirit of scientific inquiry and innovation among faculty, fellows, and students.
Our researchers study the biology, prevention, diagnosis, and treatment of gastrointestinal (GI) and liver diseases. Among our current areas of research are the following:
- role of the gut microbiome in health and the pathogenesis of disease such as colorectal cancer, liver cancer, and fatty liver and other diseases
- role of GI infection and gut microbial dysbiosis in the pathogenesis of inflammatory bowel disease
- quality and innovations in enhanced technologies for colon cancer screening
- bariatric endoscopy outcomes in obesity and fatty liver disease
- clinical trials in all areas of liver disease, inflammatory bowel disease, colorectal cancer screening and prevention, and other GI conditions
- cirrhosis and hepatitis C infection
Select Faculty Publications
Approaches to assessing completeness of polyp resections in clinical practice: a systematic scoping review
Endoscopy. 2026 Jan 14;
Age- and sex-adjusted performance of a colorectal cancer screening test using US census distribution
Journal of the National Cancer Institute. 2026 Jan 09;
Longitudinal Study of Sexual Dysfunction in Men and Women with Inflammatory Bowel Disease Initiating Biologic or Small Molecule Therapy
Digestive diseases & sciences. 2026 Jan 08;
Comparative benefits, burdens and harms of emerging blood-based tests for colorectal cancer screening
Journal of the National Cancer Institute. 2026 Jan 01; 118:113-120
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Journal of hepatology. 2026 Jan ; 84:74-85
Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States
Journal of viral hepatitis. 2026 Jan ; 33:e70119
Efficacy of etrasimod in ulcerative colitis: analysis of ELEVATE UC 52 and ELEVATE UC 12 by baseline endoscopic severity
Clinical gastroenterology & hepatology. 2026 Jan ; 24:210-220.e3
Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: a systematic review and meta-analysis
Journal of gastrointestinal oncology. 2025 Dec 31; 16:2686-2702